GeneThera announced that it has entered into a partnership agreement with Cumming Corporation. The partnership with Cumming Corporation will allow GeneThera to implement its strategy to build a global network of laboratories designed to prevent control and treat present and future pandemics. The designing of specialized, high safety level laboratory facilities has become a critical supporting component in the fight against present and future pandemics. The SARS-CoV-2 virus has changed the way life-science laboratories are designed and built. The partnership between GeneThera, Inc. and Cumming Corporation represents the first example of a multi comprehensive zoonotic diseases targeted laboratory facilities. GeneThera laboratory facilities will be divided into five laboratory areas: Genome Sequencing; Molecular Robotics and AI based Q-PCR diagnostics; Viral Molecular Therapeutics (CRISPR-Cas-13) Technology; Support Facility to Mobile Laboratories; Biosafety Level 3 (BSL) Viral Growth Facility.